BenevolentAI and Stanford University review progress in their AI research partnership, which looks at the role of context in information extraction.
Daniel Neil has been promoted to Chief Technology Officer to develop BenevolentAI’s long term technology strategy for artificial intelligence-driven drug discovery.
Joanna Shields, CEO of BenevolentAI, a clinical-stage AI drug discovery company, presented at the 40th Annual J.P. Morgan Healthcare Conference on Monday, 10th January.
The WHO has widened its COVID-19 treatment pool by adding baricitinib, the drug first identified as a COVID-19 treatment by BenevolentAI, to the top of its treatment guideline.
Joanna Shields, CEO of BenevolentAI, a clinical-stage AI drug discovery company, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, 10th January.
Joanna Shields, CEO BenevolentAI shares her reflection on Responsible AI and innovation following her recent involvement at the GPAI Summit and Paris Peace Forum.
Novel target for idiopathic pulmonary fibrosis, discovered using BenevolentAI’s AI-driven drug discovery platform, selected to enter AstraZeneca’s portfolio.
BenevolentAI’s AI-Drug Discovery platform uncovered a novel target not previously linked to ulcerative colitis and advanced candidate to preclinical studies.
Having shared our open-source Diversity Analysis Tool last year, we were tasked to investigate and demonstrate the lack of diversity in biomedical data as part of the State of AI Report 2021.
